Global Cefmetazole Market Insights, Forecast to 2028

A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted
Market Analysis and Insights: Global Cefmetazole Market
Due to the COVID-19 pandemic, the global Cefmetazole market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 1g accounting for % of the Cefmetazole global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Cefmetazole market size is valued at US$ million in 2021, while the US and Europe Cefmetazole are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cefmetazole landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Cefmetazole include Pfizer, Shinpoong Daewoo Pharma, Swiss Pharm, Tai-Yu, Nipro Pharma Nipurofama, Takeda Teva Pharma, Nichi-Iko Pharmaceutical, Daiichi Sankyo and Shin Poong, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cefmetazole Scope and Segment
Cefmetazole market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cefmetazole market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
1g
2g
Segment by Application
Hospital
Drug Store
On-line
By Company
Pfizer
Shinpoong Daewoo Pharma
Swiss Pharm
Tai-Yu
Nipro Pharma Nipurofama
Takeda Teva Pharma
Nichi-Iko Pharmaceutical
Daiichi Sankyo
Shin Poong
City and Guilds
Towa Yakuhin
He Xin Pharm
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE